Han Kun represented GSK in the China merger filing for its three-part transaction with Novartis AG involving OTC business, vaccine business and oncology business
2015-03-11
GlaxoSmithKline (GSK) successfully completed its three-part transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses.
Under the transactions, GSK acquired Novartis's global Vaccines business (excluding influenza vaccines); GSK created a new world-leading Consumer Healthcare joint venture with Novartis; and GSK divested its Oncology business for an aggregate consideration of $16 billion.
Han Kun served as GSK's sole China antitrust counsel to procure merger notification to MOFCOM.
Han Kun’s antitrust team headed by Partner Ma Chen worked on this transaction.